Treatment emergent adverse events (TEAEs) reported by >1 subject
| ONO-9054 30 μg/mL (0.003%) (N=62) | Xalatan 0.005% (N=61) | |||
|---|---|---|---|---|
| System organ class preferred term | Events | Subjects (%) | Events | Subjects (%) |
| Total number of TEAEs | 37 | 22 (35.5) | 35 | 18 (29.5) |
| Eye disorders | 31 | 21 (33.9) | 25 | 14 (23.0) |
| Conjunctival hyperaemia | 14 | 12 (19.4) | 5 | 5 (8.2) |
| Vision blurred | 3 | 3 (4.8) | 0 | 0 |
| Abnormal sensation in eye | 2 | 2 (3.2) | 2 | 2 (3.3) |
| Visual acuity reduced | 2 | 2 (3.2) | 1 | 1 (1.6) |
| Punctate keratitis | 2 | 2 (3.2) | 3 | 3 (4.9) |
| Dry eye | 1 | 1 (1.6) | 2 | 2 (3.3) |
| Eye discharge | 1 | 1 (1.6) | 3 | 2 (3.3) |
| Eye pruritus | 0 | 0 | 2 | 2 (3.3) |
| Episcleral hyperaemia | 0 | 0 | 2 | 2 (3.3) |
| General disorders and administrative site conditions | 2 | 2 (3.2) | 6 | 6 (9.8) |
| Instillation site pain | 2 | 2 (3.2) | 5 | 5 (8.2) |
| Infections and infestations | 1 | 1 (1.6) | 4 | 3 (4.9) |
| Nasopharyngitis | 0 | 0 | 2 | 2 (3.3) |
N, the number of subjects in the analysis set.